Plasma and erythrocyte relationship of catecholamines in hemodialysis patients
More details
Hide details
Department of Laboratory Diagnostic, Medical University of Lublin, Poland
Department of Nephrology, Medical University of Lublin, Poland
Department of Molecular Biology and Translational Research, Institute of Rural Health, Lublin, Poland
Department of Medical Biology and Translational Research, Faculty of Medicine, University of Information Technology and Management, Rzeszow, Poland
Ann Agric Environ Med. 2014;21(3):562–566
The function of the autonomic nervous system is based on reciprocal interaction between the sympathetic and parasympathetic parts, most frequently in the form of antagonistic action on target organs. The main mediators of the sympathetic nervous system in the effectors part are catecholamines (CA), which are involved in various physiological processes. Moreover, CA also has a profound effect on the kidneys, being factors that impact on renal haemodynamics, and have been reported to be altered in pathological disorders, e.g. extracellular volume expression, hypertension and cardiovascular complications. The increased sympathetic nerve activity, at least in part, can explain the raised in plasma CA observed in chronic kidney diseases. Furthermore, plasma CA levels in ureamic patients cannot be considered a reliable index of sympathetic activity, due to existence of many factors which may affect their values. In addition, CA released into the circulation, as one of many substances, may penetrate across the cellular membranes of erytrocytes (RBC). Taking these observations together, the aim of the presented study was to investigate for the first time the plasma and erythrocyte relationship of catecholamines in haemodialysis. The studies were performed among 37 haemodialysed patients who were inhabitants of the Lublin commune. Plasma and intracellular concentration of CA were measured prior to and following haemodialysis by high performance liquid chromatography with electrochemical detection. The results suggest that RBC are able to accumulate CA at the stage of terminal renal failure; in addition, the levels of adrenaline and dopamine in RBC depend on the accumulation of urea in plasma. It was also found that the dynamic changes in concentration of RBC adrenaline are an independent predictor of mortality in haemodialysis patients.
Sarnak MJ, Levey AS. Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J Thromb Thrombolysis. 2000; 10(2): 169–180.
Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004; 66: 1310–1314.
Axelord J, Weinshilboum R. Catecholamines. New Engl J Med. 1972; 2: 237–287.
Sarkar C, Chakroborty D, Basu S. Neurotransmitters as regulators of tumor angiogensis and immunity: the role of catecholamines. J Neuroimmune Pharmacol 2012; 10: 11481–11512.
Di Marco GS, Vio CP, Dos Santos OF, Schor N, Casarini DE. Catecholamine production along the nephron. Cell Physiol Biochem. 2007; 20: 919–924.
Książek P, Buraczyńska K, Buraczyńska M. Norepinephrine transporter gene (NET) polymorphism in patients with type 2 diabetes. Kidney Blood Press Res. 2006; 29(6): 338–343.
Ziegler MG, Morrissey EC, Kennedy B, Elayan H. Sources of urinary catecholamines in renal denervated transplant recipients. J Hypertens. 1990; 8: 927–931.
Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 2008; 117: 1277–1282.
Danon A, Sapir JD. Uptake and metabolism of catecholamines by human red blood cells. Clin Pharmacol Ther.1972; 13(6): 916–922.
Borgese F, Garcia-Romeu F, Motais R. Catecholamine-induced transport systems in trout erythrocyte. J Gen Physiol. 1986; 87: 551–566.
Azoui R, Cuche JL, Renaud JF, Safar M, Dagher G. A dopamine transporter in human erythrocytes: modulation by insulin. Exp Physiol. 1996; 81: 421–434.
Azoui R, Schneider J, Dong WX, Dabiré H, Safar M, Cuche JL. Red blood cells participate in the metabolic clearance of catecholamines in the rat. Life Sci.1997; 60(6): 358–367.
Altman RJ, Smith CC, Betteridge J. Catecholamines Content of human erythrocytes. Clin Chem. 1988; 34(10): 2120–2122.
Azoui R, Vignon D, Safar M, Cyche JL. Plasma erythrocyte relationship of catecholamines in human blood. J Cardiovasc Pharmacol 1994; 23(4): 525–531.
Solski J. The catecholamines levels in human red blood cells. Appl Biol Commun.1992; 2(4): 187–190.
Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosention F, FouadTarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992; 327: 1912–1918.
Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. Nat Rev Neurol. 2009; 5(10): 542–551.
Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004; 56: 331–349.
Boomsma F, Tipton KF. Renalase, a catecholamine-metabolising enzyme? J Neural Transm. 2007; 114: 775–776.
Buraczynska M, Zukowski P, Buraczynska K, Mozul S, Książek A. Renalase gen polimorphisms in patients with type 2 diabetes, hypertension and stroke. Neurol Med. 2011; 13: 321–327.
XuJ, Desir DV. Renalase, a new renal hormone: its role in health and disease. Curr Opin Nephrol Hypertens. 2007; 16(4).373–378.
Luft FC. Renalase, a catecholamine-metabolizing hormone from the kidney. Cell Metab. 2005; 1(6): 358–360.
Kvetnansky R, Ukropiec J, Laukova M, Manz B, Pacak K, Vargovic P. Stress stimulates production of catecholamines in rat adipocytes. Cell Mol Neurobiol. 2012; 32: 801–813.
Alexander N, Velasquez M, Vlachakis N.D. Red blood cells: in vitro site for transport and inactivation of biogenic amines in man and rats. Life Sci. 1981; 29: 477.
Gary V. Desir Role of renalase in the regulation of blood pressure and the renal dopamine system. Curr Opin Nephrol Hypertens. 2011; 20: 31–36.
Tredelenburg U. A kinetic analysis of the extraneuronal uptake and metabolism of catecholamines. Rev Biol Comm.1994; 4(5–6): 127–129.
Bonomini M, Sirolli V. Uremic toxicity and anemia. J Nephrol. 2003; 16: 21–28.
Weinstein T, Chagnac A, Korzest A, Boaz M, Ori Y, Herman M, et al. Haemolysis is haemodialysis patients: evidence for impaired defense mechanisms against oxidative stress. Nephrol Dial Transplant. 2000; 15: 883–887.
Tankiewicz A, Pawlak D, Pawlak K, Szewc D, Myśliwiec M, Buczko W. Anthranilic acid-uraemic toxin damage red cells membrane. Int Urol Nephrol. 2005; 37: 621–627.
Glorieux G, Vanholder R. New Uremic Toxins – Which solution should be removed Contrib Nephrol, Basel, Karger. Contrib Nephrol. 2011; (168): 117–128.
Antonelou MH, Kriebardis AG, Velentzas AD, Kokkalis AC, Georgakopoulou SC, Papassideri IS. Oxidative stress-associated shape transformation and membrane proteome remodeling in erythrocytes of end stage renal disease patients on hemodialysis. J Prot. 2011; 20: 1–12.
Nitta K, Akiba T, Suzuki K, Uchida K, Ogawa T, Majima K, et al. Assessment of coronary artery calcification in hemodialysis patients using Multi-Detector Spiral CT Scan. Hypertens Res. 2004; 27: 527.
Flierl MA, Rittirsch D, Huber-Lang M, Sarma JV, Ward PA. Catecholamines – crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening Pandora`s Box? Mol Med. 2008; 14(3–4): 195–204.
Currie G, Freel ME,Perry CG, Dominiczak AF. Disorders of Blood Pressure Regulation – Role of catecholamine biosynthesis, release, and metabolism. Curr Hypertens Rep. 2012; 14: 38–45.
Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et. al. Plasma Norepinephrine predicts survival and incydent cardiovacular events in patients with end-stage renal disease. Circulation 2002; 105: 1354–1359.